Endovastec(SH:688016) Sou Hu Cai Jing·2025-10-14 11:36Core Viewpoint - The stock of Xinmai Medical (688016) has shown a decline in both price and trading volume, with significant net outflows from retail and speculative investors, indicating potential concerns about the company's financial performance and market sentiment [1][2]. Financial Performance - As of the latest report, Xinmai Medical's total revenue for the first half of 2025 was 714 million yuan, representing a year-on-year decrease of 9.24% [3]. - The net profit attributable to shareholders for the same period was 315 million yuan, down 22.03% year-on-year, while the non-recurring net profit was 271 million yuan, reflecting a decline of 29.96% [3]. - The company's second-quarter performance showed a revenue of 382 million yuan, a decrease of 10.92% year-on-year, and a net profit of 185 million yuan, down 15.61% [3]. Market Position - Xinmai Medical's total market capitalization is 13.127 billion yuan, which is higher than the industry average of 11.795 billion yuan, ranking 25th in the industry [3]. - The company has a net asset value of 4.058 billion yuan, also above the industry average, ranking 34th [3]. - The price-to-earnings ratio (P/E) stands at 20.86, significantly lower than the industry average of 66.45, ranking 13th [3]. Profitability Metrics - The gross margin for Xinmai Medical is 69.19%, which is substantially higher than the industry average of 51.85%, ranking 22nd [3]. - The net profit margin is 43.48%, far exceeding the industry average of 10.39%, ranking 2nd [3]. - Return on equity (ROE) is reported at 8.16%, compared to the industry average of 1.8%, ranking 12th [3]. Investment Sentiment - In the past 90 days, 11 institutions have rated the stock, with 9 buy ratings and 2 hold ratings, indicating a generally positive outlook despite recent performance [4]. - The average target price set by institutions for Xinmai Medical is 136.03 yuan, suggesting potential upside from the current trading price [4].